Vcare PharmaTech Initiates Clinical Study of Eratrectinib (VELMARTO®) for the New Indication of Bone Metastatic Cancer Pain

　　Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) has officially launched a clinical trial for the new indication of bone metastatic cancer pain of Eratrectinib Capsules (VELMARTO®, VC004), a Class 1 innovative drug independently developed by the company. This move further expands the clinical application scope of this next-generation TRK inhibitor and explores an innovative treatment option for patients suffering from bone metastatic cancer pain.

　　Eratrectinib Capsules (VELMARTO®) is a next-generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. It received conditional marketing approval from the NMPA in June 2026 for the treatment of adult and adolescent patients aged 12 years and older with solid tumors harboring NTRK gene fusions. As a domestically developed tissue-agnostic broad-spectrum anti-tumor innovative drug, it delivers profound and durable tumor response benefits to patients with NTRK fusion-positive solid tumors, featuring potent anti-tumor activity, anti-resistance profile, favorable blood-brain barrier penetration and high safety. In September 2026, Vcare PharmaTech entered into an exclusive commercialization cooperation for Eratrectinib Capsules for NTRK fusion-positive solid tumors in mainland China with NJCTTQ.

　　Bone metastatic cancer pain is one of the most common concomitant symptoms in patients with advanced tumors and severely impairs patients’ quality of life. Leveraging the potent inhibitory effect of Eratrectinib on the TRK target, this newly launched clinical study for the bone metastatic cancer pain indication aims to explore the analgesic potential of the drug beyond anti-tumor effects and investigate the clinical value of “one drug, dual effects”, which is expected to deliver an innovative therapeutic regimen for patients with cancer pain.

　　The ongoing clinical trial is a Phase Ib, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Eratrectinib Capsules in the treatment of bone metastatic cancer pain. It will assess the safety and tolerability of the drug for moderate-to-severe bone metastatic cancer pain, determine the Recommended Phase 2 Dose (RP2D) of the drug as an adjunctive therapy to oral opioids in patients with moderate-to-severe bone metastatic cancer pain, and generate evidence to support subsequent pivotal clinical development for this indication.

　　Disclaimer

　　1.This news release is intended to share cutting-edge progress of the Company’s R&D work and is not for advertising purposes. The information herein is not directed at patients and is for reference only by healthcare professionals.

　　2.Nothing in this press release constitutes a recommendation for any medicinal product and/or indication.

　　3.Information contained in this press release is for reference only. Company press releases and announcements shall not, in any way, replace professional medical guidance nor be construed as medical advice. For information on the diagnosis and treatment of specific diseases, please follow the advice and guidance of physicians or other healthcare professionals.

　　4.This press release may contain certain forward-looking statements. Such statements inherently involve substantial risks and uncertainties. Words such as “anticipate”, “believe”, “predict”, “expect”, “intend” and other similar expressions, when used in relation to the Company, identify forward-looking statements. The Company undertakes no obligation to continuously update such predictive statements.

　　These forward-looking statements are based on management’s current views, assumptions, expectations, estimates and understanding of future events at the time the statements are made. They are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and difficult to predict. Accordingly, actual results may differ materially from those expressed or implied in the forward-looking statements due to future changes and developments in our business, competitive landscape, political, economic, legal and social conditions.

　　Neither the Company, its directors nor its agents or employees shall have any obligation (a) to correct or update any forward-looking statements posted on this website; or (b) to accept any liability arising from the failure of any forward-looking statements to materialize or from their becoming inaccurate.